Short blinatumomab before stem cell transplant for low B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a short course of blinatumomab (a targeted immunotherapy) given before a stem cell transplant in people with low amounts of B-ALL leukemia. The goal is to prepare the body for transplant and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 16 years old.
- You must have a diagnosis of B-cell acute lymphoblastic leukemia (B-ALL).
- You must have medical records showing your disease status before and after a stem cell transplant.
- You cannot have received blinatumomab treatment for more than 14 days.
- Your leukemia must not be widespread (less than 10% of cells in your bone marrow or blood).
- You must not have severe organ problems (heart, liver, kidney, or digestive) or leukemia that has spread to the brain/spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if blinatumomab, an immunotherapy drug, can prevent B-cell acute lymphoblastic leukemia (B-ALL) from coming back in people who have already had a donor stem cell transplant. You may qualify if you had a relapse before transplant or had a positive minimal residual disease test, and if you are now in complete remission after the transplant.
This trial tests whether the drug blinatumomab, given after a stem cell transplant, can help prevent high-risk B-ALL from coming back. It is for people who have already had a transplant and meet certain health criteria.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
This trial tests a combination of low-intensity chemotherapy and a short course of blinatumomab (a targeted immunotherapy) in adults with a certain type of acute leukemia. The goal is to see if this approach helps prepare patients for a stem cell transplant with fewer side effects.
This trial tests if a targeted drug, blinatumomab, can help prevent leukemia from coming back after a stem cell transplant. It is for people with high-risk B-cell acute lymphoblastic leukemia who have achieved remission but are at high risk of relapse.
Hear when a new Leukemia, Lymphoid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.